Diabetes device makers fall after data on Lilly's weight loss pill
View all comments(0)
Shares of diabetes device makers fall between 1% to 3% before the bell
Eli Lilly LLY.N says its oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial
Shares of Dexcom DXCM.O, which manufactures continuous glucose monitors, down 2.6% at $66.94 premarket
Shares of insulin pump makers Tandem Diabetes Care TNDM.O and Insulet Corp PODD.O down around 2% each
LLY shares rise 13.4% to $833.56 premarket
As of last close, DXCM down 11.6%, TNDM down 52.1%, LLY down 4.8%, PODD down 4% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.